Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
... Nano Research , an English-language journal jointly published by ... the Science Citation Index-Expanded (SCI-E). The academic journal, ... index from Volume 1, Issue 1. Nano Research ... a collection comprising more than 90 journals. ...
... March 17  OriGene Technologies, Inc., a ... a $16 million Series B financing led ... Zero2IPO. OriGene,s previous investors Morningside Venture Investments ... this round.  The proceeds from the funding will be ...
... , ... highlight need for innovation to meet growing global needs sustainably. , ... Washington, DC (PRWEB) March 17, 2010 ... range of benefits modern agriculture has provided to society and emphasized the importance of ...
Cached Biology Technology:China's first open-access journal Nano Research listed in Science Citation Index 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 3Global Food Security Depends on Modern Agriculture 2Global Food Security Depends on Modern Agriculture 3Global Food Security Depends on Modern Agriculture 4
(Date:8/20/2014)... POINT ROBERTS, Washington , August 20, 2014 /PRNewswire/ ... in Addressing Security Concerns in the Payment Industry?   ... covering leading sectors including biometrics, issues commentary from analysts and ... Jason Peaslee , Managing Partner at Thrive Analytics, Isabelle ... , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), ...
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... Efforts must be made to decrease China,s increasing caesarean ... August) in BJOG: An International Journal of Obstetrics ... the highest caesarean delivery rates in the world. Of ... by caesarean. Although the exact rate is not known, ... China reports total caesarean rates ranging from 36% to ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... MADISON A discovery at the University of Wisconsin-Madison ... create a "hydrogen economy" that would use this abundant ... hydrogen is the ultimate non-carbon, non-polluting fuel for storing ... for energy, hydrogen produces water but no carbon dioxide. ...
... the bacteria that form the base of the ocean,s ... a new study. In climate change, as in ... dioxide levels and temperature rise globally, scientists increasingly want ... perish in the environment of tomorrow. The answer ...
... Brookhaven National Laboratory have identified two promising candidates for ... of ailments ranging from colds to gastrointestinal disorders to ... , a journal of the Federation of European Biochemical ... compounds to determine which might block the effects of ...
Cached Biology News:New catalyst could cut cost of making hydrogen fuel 2Greenhouse gas likely altering ocean foodchain 2Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
Request Info...
... Platypus Contact Printing Kit contains choice of Printing Surface ... Gold over Ti adhesion layer, 1 silicon wafer coated ... or 3 plain glass slides), PDMS Stamps (3 PDMS ... squares or 100 um x 10 mm or 200 ...
Biology Products: